

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## Medical Policy



### Title: Intensity Modulated Radiotherapy (IMRT)

Related Policies:	▪ <i>Stereotactic Radiosurgery and Stereotactic Radiotherapy Body</i>
-------------------	---

<b>Professional / Institutional</b>
Original Effective Date: January 1, 2002 / March 2, 2009
Latest Review Date: May 26, 2026
Current Effective Date: May 26, 2026

**Retired Date: May 26, 2026**

State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact [Blue Cross and Blue Shield of Kansas Customer Service](#).

The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.

The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.

If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.

### DESCRIPTION

Radiotherapy (RT) is an integral component in the treatment of many cancers. Intensity-modulated radiotherapy (IMRT) has been proposed as a method of external beam radiotherapy that delivers adequate radiation to the tumor while minimizing the radiation dose to surrounding normal tissues and critical structures.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## **OBJECTIVE**

The objective of this policy is to determine whether the use of intensity-modulated radiotherapy improves the net health outcome when used to treat certain cancers.

## **BACKGROUND**

For certain stages of many cancers, randomized controlled trials have shown that postoperative RT improves outcomes for operable patients. Adding radiation to chemotherapy also improves outcomes for those with inoperable tumors that have not metastasized beyond regional lymph nodes.

## **RADIOTHERAPY TECHNIQUES**

### **Conventional External-Beam Radiation Therapy**

Methods to plan and deliver radiation therapy have evolved in ways that permit more precise targeting of tumors with complex geometries. Most early trials used 2-dimensional treatment planning, based on flat images and radiation beams with cross-sections of uniform intensity that were sequentially aimed at the tumor along 2 or 3 intersecting axes. Collectively, these methods are termed *conventional external beam radiation therapy*.

### **Three-Dimensional Conformal Radiotherapy**

Treatment planning evolved by using 3-dimensional images, usually from computed tomography (CT) scans, to delineate the boundaries of the tumor and discriminate tumor tissue from adjacent normal tissue and nearby organs at risk for radiation damage. Computer algorithms were developed to estimate cumulative radiation dose delivered to each volume of interest by summing the contribution from each shaped beam. Methods also were developed to position the patient and the radiation portal reproducibly for each fraction and immobilize the patient, thus maintaining consistent beam axes across treatment sessions. Collectively, these methods are termed *3-dimensional conformal radiation therapy (3D-CRT)*.

### **Intensity-Modulated Radiotherapy**

Intensity-modulated radiotherapy (IMRT), which uses computer software, CT images, and magnetic resonance imaging (MRI), offers better conformality than 3D-CRT as it is able to modulate the intensity of the overlapping radiation beams projected on the target and to use multiple-shaped treatment fields. Treatment planning and delivery are more complex, time-consuming, and labor intensive for IMRT than for 3D-CRT. The technique uses a multileaf collimator (MLC), which, when coupled with a computer algorithm, allows for "inverse" treatment planning. The radiation oncologist delineates the target on each slice of a CT scan and specifies the target's prescribed radiation dose, acceptable limits of dose heterogeneity within the target volume, adjacent normal tissue volumes to avoid, and acceptable dose limits within the normal tissues. Based on these parameters and a digitally reconstructed radiographic image of the tumor, surrounding tissues, and organs at risk, computer software optimizes the location, shape, and intensities of the beams ports to achieve the treatment plan's goals.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

Increased conformality may permit escalated tumor doses without increasing normal tissue toxicity and thus may improve local tumor control, with decreased exposure to surrounding normal tissues, potentially reducing acute and late radiation toxicities. Better dose homogeneity within the target may also improve local tumor control by avoiding underdosing within the tumor and may decrease toxicity by avoiding overdosing.

Technologic development has produced advanced techniques that may further improve RT treatment by improving dose distribution. These techniques are considered variations of IMRT. Volumetric modulated arc therapy (VMAT) delivers radiation from a continuous rotation of the radiation source. The principal advantage of VMAT is greater efficiency in treatment delivery time, reducing radiation exposure and improving target radiation delivery due to less patient motion. Image-guided RT involves the incorporation of imaging before and/or during treatment to more precisely deliver RT to the target volume.

IMRT methods to plan and deliver RT are not uniform. IMRT may use beams that remain on as MLCs move around the patient (dynamic MLC) or that are off during movement and turn on once the MLC reaches prespecified positions ("step and shoot" technique). A third alternative uses a very narrow single beam that moves spirally around the patient (tomotherapy). Each method uses different computer algorithms to plan treatment and yields somewhat different dose distributions in and outside the target. Patient position can alter target shape and thus affect treatment plans. Treatment plans are usually based on 1 imaging scan, a static 3D-CT image. Current methods seek to reduce positional uncertainty for tumors and adjacent normal tissues by various techniques. Patient immobilization cradles and skin or bony markers are used to minimize day-to-day variability in patient positioning. In addition, many tumors have irregular edges that preclude drawing tight margins on CT scan slices when radiation oncologists contour the tumor volume. It is unknown whether omitting some tumor cells or including some normal cells in the resulting target affects outcomes of IMRT.

Investigators are exploring an active breathing control device combined with moderately deep inspiration breath-holding techniques to improve conformality and dose distributions during IMRT for breast cancer.<sup>1</sup> Techniques presently being studied with other tumors (e.g., lung cancer)<sup>2</sup> either gate beam delivery to the patient's respiratory movement or continuously monitor tumor (by in-room imaging) or marker (internal or surface) positions to aim radiation more accurately at the target. The impact of these techniques on outcomes of 3D-CRT or IMRT for breast cancer is unknown. However, it appears likely that respiratory motion alters the dose distributions actually delivered while treating patients from those predicted by plans based on static CT scans or measured by dosimetry using stationary (nonbreathing) targets.

Note the evidence for the following abdominal and pelvic cancers has not yet been reviewed and is beyond the scope of this document: bladder, kidney, ureter, and esophageal cancer and sarcoma.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## **REGULATORY STATUS**

In general, IMRT systems include intensity modulators, which control, block, or filter the intensity of radiation; and RT planning systems, which plan the radiation dose to be delivered.

A number of intensity modulators have received marketing clearance through the U.S. Food and Drug Administration (FDA) 510(k) process. Intensity modulators include the Innocure Intensity Modulating Radiation Therapy Compensators (Innocure) and Decimal Tissue Compensator (Southeastern Radiation Products, now called .decimal) cleared in 2006. FDA product code: IXI. Intensity modulators may be added to standard linear accelerators to deliver IMRT when used with proper treatment planning systems.

RT planning systems have also been cleared for marketing by FDA through the 510(k) process. These include the Prowess Panther™ (Prowess) in 2003, TiGRT (LinaTech) in 2009, the RayDose (now RayStation, RaySearch Laboratories) in 2008, and the eIMRT Calculator (Standard Imaging). FDA product code: MUJ.

Fully integrated IMRT systems are also available. These devices are customizable and support all stages of IMRT delivery, including planning, treatment delivery, and health record management. One such device to receive FDA 510(k) clearance is the Varian IMRT system (Varian Medical Systems). FDA product code: IYE.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## **POLICY**

A. Intensity modulated radiotherapy (IMRT) is considered **medically necessary** for the following indications:

1. Prostate cancer
  - a. As definitive treatment for non-metastatic and appropriate oligometastatic cases of prostate cancer using standard fractionation or equivalent hypofractionated schedules (e.g., 7920 cGy in 44 fractions, 7800 cGy in 39 fractions, 7000 cGy in 28 fractions, 6000 cGy in 20 fractions).
  - b. As adjuvant or salvage radiation therapy with curative intent for men who are post-prostatectomy, with biochemical failure, and without distant metastasis when >64 Gy in standard fractionation or equivalent hypofractionation will be given.
2. Head and neck cancer, with the exception of patients with early stage laryngeal cancer (stage I and II).
3. Cancer involving the CNS.
4. Carcinoma of the anus or vulva.
5. Anaplastic thyroid cancer.
6. Carcinoma of the cervix.
7. Whole pelvic radiotherapy for gynecologic malignancies.
8. Pediatric tumors (e.g., Ewing's sarcoma, Wilms' tumor).
9. Breast cancer, when at least one of the following is met:
  - a. Left breast cancer

**OR**

  - b. Right breast cancer

**WITH**

  - i. Lung—3D results in  $\geq 30\%$  of ipsilateral lung receiving  $\geq 20$  Gy, OR 3D results in  $\geq 20\%$  of combined lung volume receiving  $\geq 20$ Gy;

**OR**

  - ii. Skin / Soft Tissue—3D results in  $\geq 5\%$  of intended breast receiving  $\geq 7\%$  of prescribed dose OR Medial lesion where 3D results in  $\geq 10\%$  of contralateral breast receiving  $\geq 10$ Gy.
10. Esophagus, Stomach, Pancreas, Hepatobiliary Tract, Rectum, Colon, Small Bowel, when at least one of the following is met:

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

- a. Heart—3D result in  $\geq 50\%$  of heart receiving  $\geq 30$  Gy,  
**OR**
- b. Lung—3D results in  $\geq 30\%$  of combined lung volume receiving  $\geq 20\%$  Gy,  
**OR**  
Mean lung dose  $\geq 20$  Gy;  
**OR**
- c. Spinal Cord—3D result in any portion of the spinal cord receiving a dose above 45 Gy;  
**OR**
- d. Liver—3D results in  $\geq 60\%$  of liver volume receiving  $\geq 30$  Gy,  
**OR**  
Mean liver dose  $\geq 32$  Gy;  
**OR**
- e. Kidney—3D results in  $\geq 33\%$  of combined kidney volume receiving  $\geq 20$  Gy (two functional kidneys are present);  
**OR**  
For one functioning kidney or kidney transplant, IMRT provides a lower dose than achievable with 3D;  
**OR**
- f. Small Intestine—3D results in  $\geq 195$ cc of small intestine receiving  $\geq 45$  Gy;  
**OR**
- g. Stomach—3D results in  $\geq 10\%$  of stomach receiving  $\geq 45$  Gy  
**OR**  
5% receiving  $\geq 50$  Gy;  
**OR**
- h. Femoral head—3D results in a femoral head receiving  $\geq 45$  Gy.

#### 11. Stage III Lung cancer

#### 12. Lymphomas or Sarcomas of Retroperitoneum, Chest Wall and Thorax, when at least one of the following is met:

- a. Heart—3D results in  $\geq 50\%$  of heart receiving  $\geq 30$  Gy;  
**OR**
- b. Lung—3D results in  $\geq 30\%$  of combined lung volume receiving  $\geq 20$  Gy  
**OR**
- c. Mean lung dose of  $\geq 20$  Gy;  
**OR**
- d. Spinal cord—3D results in any portion of the spinal cord receiving a dose above 45 Gy  
**OR**
- e. Liver—3D results in 60% of liver volume receiving  $\geq 30$  Gy  
**OR**
- f. Mean liver dose  $\geq 32$  Gy;  
**OR**

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

- g. Femoral head—3D results in a femoral head receiving  $\geq 45$  Gy;  
**OR**
- h. Small intestine—3D results in  $\geq 195$  cc of small intestine receiving  $\geq 45$  Gy;  
**OR**
- i. Stomach—3D results in  $\geq 10\%$  of stomach receiving  $\geq 45$  Gy  
**OR**  
5% receiving  $\geq 50$  Gy;  
**OR**
- j. Rectosigmoid—3D results in  $\geq 60\%$  of rectosigmoid area receiving  $\geq 30$  Gy;  
**OR**
- k. Bladder—3D results in  $\geq 35\%$  of bladder receiving  $\geq 45$  Gy;  
**OR**
- l. Kidney—3D results in 33% of combined kidney volume receiving  $\geq 20$  Gy (two functional kidneys are present)  
**OR**  
For one functioning kidney or kidney transplant IMRT provides a lower dose than achievable with 3D.

- 13. Sarcomas of the Extremities, when at least one of the following is met:
  - a. Head / Neck—IMRT covered if head and neck structures would receive any radiation via 3D;  
**OR**
  - b. Femur—3D results in  $\geq 50\%$  of contiguous femur cortex receiving  $\geq 50$  Gy
- 14. Individuals who require repeat irradiation of a field that has received prior irradiation.
- 15. Radiosensitive tumors where critical structures cannot be adequately protected with standard 3D conformal radiotherapy. Medical necessity for the use of IMRT for these other indications will be considered individually and will require supporting records from the treating radiation oncologist including the 3-D dose volume histogram documenting the need for IMRT.

B. Other applications of IMRT are considered **not medically necessary**.

C. DOCUMENTATION: As recommended by ASTRO, the IMRT treatment record must support:

- 1. The reasonable and necessary requirements as outlined in the Policy section.
- 2. The plan which defines the goals and requirements of the treatment plan, including the specific dose objectives to the target and nearby critical structures.
- 3. A note of medical necessity for IMRT by the treating physician.
- 4. Signed IMRT plan that corresponds with the approved prescription.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

5. The medical record must include the following:
  - a. Documentation of clinically appropriate GTV/CTV/ITV/PTV.
  - b. Documentation of dose volume histograms for targets and OAR's.
  - c. Documentation of immobilization and patient positioning.
6. Independent basic dose calculations of monitor units have been performed for each beam before the patient's first treatment.
7. Documentation of fluence distributions (re-computed and measured in a phantom or dosimetry measuring device) is required.
8. Documentation supporting identification of structures that transverse high-and low-dose regions created by respiration is indicated when billing for respiratory motion management stimulation.

NOTE: Comparison 3D-CRT dose volume histogram (DVH) in color

### **POLICY GUIDELINES**

- A. The American Society for Therapeutic Radiology and Oncology (ASTRO) 2024 has a model policy which describes the indications for IMRT:

IMRT is considered reasonable and medically necessary in instances where sparing the surrounding normal tissue is of added benefit to the patient. Examples of reasons why IMRT might be advantageous include the following:

1. Instances in which clinically relevant tolerances of normal tissues are exceeded for a single plan or in the re-irradiation setting.
2. IMRT is indicated if the patient's general medical condition (namely, the performance status) justifies aggressive local therapy to one or more deposits of metastatic cancer in an effort to achieve total disease clearance in the setting of oligometastatic disease.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## CODING

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.

Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

The code(s) listed below are medically necessary **ONLY** if the procedure is performed according to the "Policy" section of this document.

CPT/HCPCS	
77338	Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
77402	Radiation treatment delivery, Level 1 (eg, single-electron field, multiple-electron fields, or 2D photons), including imaging guidance, when performed
77407	Radiation treatment delivery, Level 2 single-isocenter (eg, 3D or IMRT), photons, including imaging guidance, when performed
77412	Radiation treatment delivery, Level 3 multiple isocenters with photon therapy (eg, 2D, 3D, or IMRT) or a single-isocenter photon therapy (eg, 3D or IMRT) with active motion management, or total skin electrons, or mixed-electron/ photon field(s), including imaging guidance, when performed

REVISIONS	
01-30-2009	<p>Policy first published on <a href="http://www.bcbsks.com">www.bcbsks.com</a>.</p> <p>In policy section:</p> <ul style="list-style-type: none"> <li>▪ Added the following indications: <ul style="list-style-type: none"> <li>D. IMRT is considered medically necessary for treatment of <u>anal cancers</u>.</li> <li>E. IMRT may also be medically necessary for other radiosensitive tumors where critical structures cannot be adequately protected with standard 3D conformal radiotherapy. Medical necessity for the use of IMRT for these other indications will be considered individually and will require supporting records from the treating radiation oncologist including the dose volume histograms documenting the need for IMRT as opposed to conventional radiation therapy.</li> </ul> </li> </ul> <p>The American Society for Therapeutic Radiology and Oncology (ASTRO) has a model policy which describes the indications for IMRT:</p> <p>"IMRT is not a replacement therapy for conventional or three-dimensional conformal radiation therapy methods. IMRT is considered reasonable and necessary in instances where sparing the surrounding normal tissue is of added benefit and at least one of the following conditions is met:</p>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<ol style="list-style-type: none"> <li>1. The target volume is in close proximity to critical structures that must be protected.</li> <li>2. The volume of interest must be covered with narrow margins to adequately protect immediately adjacent structures.</li> <li>3. An immediately adjacent area has been previously irradiated and abutting portals must be established with high precision.</li> <li>4. The target volume is concave or convex, and critical normal tissues are within or around that convexity or concavity.</li> <li>5. Dose escalation is planned to deliver radiation doses in excess of those commonly utilized for similar tumor with conventional treatments."</li> <li>F. Other applications of IMRT are considered not medically necessary.</li> </ol> <ul style="list-style-type: none"> <li>▪ Added the following documentation information: <b>DOCUMENTATION</b> As recommended by ASTRO, documentation in the patient's medical records must support: <ol style="list-style-type: none"> <li>1. The reasonable and necessary requirements as outlined in the Policy section.</li> <li>2. The prescription must define the dose to the target and the dose constraints to the nearby critical structures.</li> <li>3. A note of medical necessity for IMRT, by the treating physician.</li> <li>4. Signed IMRT inverse plan that meets prescribed dose constraints for the planning target volume (PTV) and surrounding normal tissue.</li> <li>5. The target verification methodology must include the following: <ol style="list-style-type: none"> <li>a. Documentation of the clinical treatment volume (CTV) and the planning target volume (PTV).</li> <li>b. Documentation of immobilization and patient positioning.</li> </ol> </li> <li>6. Independent basic dose calculations of monitor units have been performed for each beam before the patient's first treatment.</li> <li>7. Documentation of fluence distributions (re-computed and measured in a phantom or dosimetry measuring device) is required.</li> <li>8. Identification of structures that transverse high-and low-dose regions created by respiration is indicated. Voluntary breath-holding alone is not a satisfactory solution for accounting for organ motion.</li> </ol> </li> </ul>
	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Reflected the applicable CPT codes 77300, 77301, 77332, 77333, 77334, 77418, 0073T</li> </ul>
01-01-2010	<p>In Coding Section:</p> <ul style="list-style-type: none"> <li>▪ Added CPT Code: 77388</li> </ul>
10-11-2011	<p>In the Policy section:</p> <ul style="list-style-type: none"> <li>▪ Item D, removed "anal cancers" and added "squamous cell carcinoma of the anus."</li> <li>▪ Added Item " E. IMRT is considered medically necessary in the treatment of individuals with anaplastic thyroid cancer."</li> <li>▪ Added Item "F. IMRT is considered medically necessary in individuals with pediatric tumors (e.g., Ewing Sarcoma, Wilms' Tumor)."</li> <li>▪ Added Item "G. IMRT is considered medically necessary in individuals who require repeat irradiation of a field that has received prior irradiation."</li> </ul> <p>Updated the Reference section.</p>
07-13-2012	<p>Updated the Description section.</p> <p>In the Policy section:</p> <ul style="list-style-type: none"> <li>▪ Added the following indication: "F. Carcinoma of the cervix."</li> </ul>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ Added the following indication: "G. Whole pelvic radiotherapy for gynecologic malignancies."</li> <li>▪ In Item J, inserted "3-D" to read "radiation oncologist including the 3-D dose volume..."</li> <li>▪ In Item J, changed "histograms" to "histogram"</li> <li>▪ In Item J, removed "as opposed to conventional radiation therapy" from the end of paragraph.</li> </ul>
	<p>In the Documentation section:</p> <ul style="list-style-type: none"> <li>▪ Revised the following language: "As recommended by ASTRO, documentation in the patient's medical records must support:               <ol style="list-style-type: none"> <li>1. The reasonable and necessary requirements as outlined in the Policy section.</li> <li>2. The prescription must define the dose to the target and the dose constraints to the nearby critical structures.</li> <li>3. A note of medical necessity for IMRT, by the treating physician.</li> <li>4. Signed IMRT inverse plan that meets prescribed dose constraints for the planning target volume (PTV) and surrounding normal tissue.</li> <li>5. The target verification methodology must include the following:                   <ol style="list-style-type: none"> <li>a. Documentation of the clinical treatment volume (CTV) and the planning target volume (PTV).</li> <li>b. Documentation of immobilization and patient positioning.</li> </ol> </li> <li>6. Independent basic dose calculations of monitor units have been performed for each beam before the patient's first treatment.</li> <li>7. Documentation of fluence distributions (re-computed and measured in a phantom or dosimetry measuring device) is required.</li> <li>8. Identification of structures that transverse high-and low-dose regions created by respiration is indicated. Voluntary breath-holding alone is not a satisfactory solution for accounting for organ motion."</li> </ol> </li> </ul>
	<p>In the Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added the following Diagnosis codes: 180.0-180.9, 182.0-182.8, V10.40, V10.41</li> </ul>
	<p>Updated Reference section.</p>
10-15-2012	<p>In the Policy section:</p> <ul style="list-style-type: none"> <li>▪ Added statement, "IMRT is considered medically necessary for the following indications:" to the beginning of the policy section.</li> <li>▪ In Item A, removed "IMRT of the prostate is considered medically necessary in patients with non-metastatic..." and added "of the prostate" to read "Prostate cancer for dose escalation &gt;75Gy of the prostate and for..."</li> <li>▪ In Item B, removed, "IMRT is considered medically necessary in the treatment of patients with" to read "head and neck cancer, with the exception..."</li> <li>▪ In item C, removed "IMRT is considered medically necessary in patients with CNS lesions" and added "Cancer involving the CNS"</li> <li>▪ In Item D, removed IMRT is considered medically necessary for patients of squamous cell" and added "or vulva" to read "Carcinoma of the anus and vulva."</li> <li>▪ In Item E, removed "IMRT is considered medically necessary in the treatment of individuals with" to read "Anaplastic thyroid cancer."</li> <li>▪ In Item H, removed "IMRT is considered medically necessary in individuals with" to read "Pediatric tumors (e.g., Ewing Sarcoma, Wilms' Tumor)."</li> <li>▪ Added Item I, "Breast cancer when at least one of the following is met:</li> </ul>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

## REVISIONS

9. Heart—3D results in  $\geq 25\%$  of heart receiving  $\geq 30\text{Gy}$ ; OR
10. Lung—3D results in  $\geq 30\%$  of ipsilateral lung receiving  $\geq 20\text{ Gy}$ , OR  
3D results in  $\geq 20\%$  of combined lung volume receiving  $\geq 20\text{Gy}$ ; OR
11. Skin / Soft Tissue—3D results in  $\geq 5\%$  of intended breast receiving  $\geq 7\%$  of prescribed dose OR  
Medial lesion where 3D results in  $\geq 10\%$  of contralateral breast receiving  $\geq 10\text{Gy}$ ."
- Added Item J, "Esophagus, Stomach, Pancreas, Hepatobiliary Tract, Rectum, Colon, Small Bowel, when at least one of the following is met:
  1. Heart—3D result in  $\geq 50\%$  of heart receiving  $\geq 30\text{ Gy}$ , OR
  2. Lung—3D results in  $\geq 30\%$  of combined lung volume receiving  $\geq 20\% \text{ Gy}$ , OR  
Mean lung dose  $\geq 20\text{ Gy}$ ; OR
  3. Spinal Cord—3D result in any portion of the spinal cord receiving a dose above  $45\text{ Gy}$ ; OR
  4. Liver—3D results in  $\geq 60\%$  of liver volume receiving  $\geq 30\text{ Gy}$ , OR  
Mean liver dose  $\geq 32\text{ Gy}$ ; OR
  5. Kidney—3D results in  $\geq 33\%$  of combined kidney volume receiving  $\geq 20\text{ Gy}$  (two functional kidneys are present); OR  
For one functioning kidney or kidney transplant, IMRT provides a lower dose than achievable with 3D; OR
  6. Small Intestine—3D results in  $\geq 195\text{cc}$  of small intestine receiving  $\geq 45\text{ Gy}$ ; OR
  7. Stomach—3D results in  $\geq 10\%$  of stomach receiving  $\geq 45\text{ Gy}$  OR  
 $5\%$  receiving  $\geq 50\text{ Gy}$ ; OR
  8. Femoral head—3D results in a femoral head receiving  $\geq 45\text{ Gy}$ ."
- Added Item K, "Lung, when at least one of the following is met:
  1. Heart—3D results in  $\geq 50\%$  of heart receiving  $\geq 30\text{ Gy}$ ; OR
  2. Lung—3D result in  $\geq 30\%$  of non-cancerous combined lung volume receiving  $\geq 20\text{ Gy}$ "
- Added Item L, "Lymphomas or Sarcomas of Retroperitoneum, Chest Wall and Thorax, when at least one of the following is met:
  1. Heart—3D results in  $\geq 50\%$  of heart receiving  $\geq 30\text{ Gy}$ ; OR
  2. Lung—3D results in  $\geq 30\%$  of combined lung volume receiving  $\geq 20\text{Gy}$  OR  
Mean lung dose of  $\geq 20\text{ Gy}$ ; OR
  3. Spinal cord—3D results in any portion of the spinal cord receiving a dose above  $45\text{ Gy}$  OR
  4. Liver—3D results in  $60\%$  of liver volume receiving  $\geq 30\text{ Gy}$  OR  
Mean liver dose  $\geq 32\text{ Gy}$ ; OR
  5. Femoral head—3D results in a femoral head receiving  $\geq 45\text{ Gy}$  OR
  6. Small intestine—3D results in  $\geq 195\text{cc}$  of small intestine receiving  $\geq 45\text{ Gy}$ ; OR
  7. Stomach—3D results in  $\geq 10\%$  of stomach receiving  $\geq 45\text{ Gy}$  OR  
 $5\%$  receiving  $\geq 50\text{ Gy}$ ; OR
  8. Rectosigmoid—3D results in  $\geq 60\%$  of rectosigmoid area receiving  $\geq 30\text{ Gy}$ ; OR
  9. Bladder—3D results in  $\geq 35\%$  of bladder receiving  $\geq 45\text{ Gy}$ ; OR
  10. Kidney—3D results in  $33\%$  of combined kidney volume receiving  $\geq 20\text{ Gy}$  (two functional kidneys are present) OR  
For one functioning kidney or kidney transplant IMRT provides a lower dose than achievable with 3D."
- Added Item M, "Sarcomas of the Extremities, when at least one of the following is met:

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<p>1. Head / Neck—IMRT covered if head and neck structures would receive any radiation via 3D; OR</p> <p>2. Femur—3D results in <math>\geq 50\%</math> of contiguous femur cortex receiving <math>\geq 50</math> Gy"</p> <ul style="list-style-type: none"> <li>▪ In Item N, removed "IMRT is considered medically necessary in" to read "Individuals who require repeat irradiation..."</li> <li>▪ In Item O, removed "IMRT may also be medically necessary for" to read "Other radiosensitive tumors where critical structures..."</li> </ul> <p>In the Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added Diagnosis codes: 174.0-174.9</li> </ul>
12-11-2013	<p>Policy reviewed.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 Diagnosis codes. <i>(Effective October 1, 2014)</i></li> </ul> <p>Updated Reference section.</p>
01-01-2015	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added CPT/HCPCS Codes: 77385, 77386, G6015, G6016 (Effective January 1, 2015)</li> <li>▪ Deleted CPT Codes: 77418, 0073T (Effective January 1, 2015)</li> </ul>
10-13-2015	<p>Updated Description section.</p> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item O, updated ASTRO medical policy indications, removed "IMRT is not a replacement therapy for conventional or three-dimensional conformal radiation therapy methods.," "clinical," "and at least one of the following conditions is met," and added "to the patient. Examples of reasons why IMRT might be advantageous include the following," to read, "IMRT is considered reasonable and necessary in instances where sparing the surrounding normal tissue is of added clinical benefit to the patient. Examples of reasons why IMRT might be advantageous include the following:"</li> <li>▪ In Item O 1, removed "that must be protected" and added "one or more" and "and a steep dose gradient outside the target must be achieved and avoid exceeding the tolerance dose to the critical structure(s)" to read, "The target volume is in close proximity to one or more critical structures and a steep dose gradient outside the target must be achieved and avoid exceeding the tolerance dose to the critical structure(s)."</li> <li>▪ In Item O 2, removed previous language and added "A decrease in the amount of dose inhomogeneity in a large treatment volume is required to avoid an excessive dose "hotspot" within the treated volume to avoid excessive early or late normal tissue toxicity."</li> <li>▪ Added new Item O 3.</li> <li>▪ In Item O 4 (previous Item O 3), removed, "and abutting portals must be established with high precision" and added "The same or" and "and the dose distribution within the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue" to read, "The same or an immediately adjacent area has been previously irradiated, and the dose distribution within the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue."</li> <li>▪ Removed previous Items O 4 and 5.</li> </ul> <p>Under "Documentation":</p> <ul style="list-style-type: none"> <li>▪ In Item 2, removed "defining the dose to the target and" and added "which defines the goals and requirements of the treatment plan," and "specific" to read, "The</li> </ul>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<p>prescription which defines the goals and requirements of the treatment plan, including the specific dose constraints to the target and nearby critical structures."</p> <ul style="list-style-type: none"> <li>▪ In Item 5, removed "including" and added "must include" to read, "The target verification methodology must include the following:"</li> <li>▪ In Item 7, added "is required" to read, "Documentation of fluence distributions (re-computed and measured in a phantom or dosimetry measuring device) is required."</li> </ul> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ In first bullet, removed "that specifically described IMRT:" and "(Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session)" and "(compensator-based beam modulated treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator convergent beam modulated fields, per treatment session), were," and added "was" to read, "Effective in 2015, code 77418 and 0073T were deleted and new codes for simple and complex IMRT delivery were created: 77385, 77386."</li> </ul> <p>Updated References section.</p>
10-26-2016	<p>Updated Description section.</p> <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ Under Documentation, removed "include" and added "support" to read, "As recommended by ASTRO, the IMRT treatment record must support:"</li> <li>▪ Under Documentation Item 6, added "have been" to read, "Independent basic dose calculations of monitor units have been performed for each beam before the patient's first treatment."</li> </ul> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Updated coding bullets.</li> </ul> <p>Updated References section.</p>
03-15-2017	<p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: C51.0, C51.1, C51.2, C51.8, C51.9, C52, C53.0, C53.1, C53.8, C53.9, C54.0, C54.1, C54.2, C54.3, C54.8, C54.9, C56.1, C56.2, C57.01, C57.02, C57.11, C57.12, C57.21, C57.22, C57.3, C57.4, C57.7, C57.8, C58, C79.61, C79.62, C79.82, C79.89, D39.11, D39.12, D39.8.</li> </ul>
08-15-2017	<p>Title changed from "Intensity Modulated Radiation Therapy (IMRT)."</p> <p>Updated Description section.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Updated coding bullets.</li> </ul> <p>Updated References.</p>
10-01-2018	<p>Updated Description section.</p> <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Removed ICD-9 codes.</li> <li>▪ Added ICD-10 codes: C43.111, C43.112, C43.121, C43.122, C44.1021, C44.1022, C44.1091, C44.1092, C44.1121, C44.1122, C44.1191, C44.1192, C44.1221, C44.1222, C44.1291, C44.1292, C44.1321, C44.1322, C44.1391, C44.1392, C44.1921, C44.1922, C44.1991, C44.1992, D03.111, D03.112, D03.121, D03.122.</li> <li>▪ Removed ICD-10 codes: C43.11, C43.12, C44.102, C44.109, C44.112, C44.119, C44.122, C44.129, C44.191, C44.192, C44.199, D03.11, D03.12.</li> </ul> <p>Updated References section.</p>
08-14-2019	<p>Updated Description section.</p>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item I A 1, removed "for dose escalation &gt;75 Gy of the prostate and for postoperative radiation of the prostate to a dose of at least 6300 cGy" and replaced with "1. As a definitive treatment for non-metastatic and appropriate oligometastatic cases of prostate cancer using standard fractionation or equivalent hypofractionated schedules (e.g., 7920 cGy in 44 fractions, 7800 cGy in 39 fractions, 7000 cGy in 28 fractions, 6000 cGy in 20 fractions). 2. As adjuvant or salvage radiation therapy with curative intent for individuals who are post-prostatectomy, with biochemical failure, and without distant metastasis when &gt;64 Gy in standard fractionation or equivalent hypofractionation will be given."</li> </ul> <p>Updated References section.</p>
06-12-2020	<p>In Policy Documentation section:</p> <ul style="list-style-type: none"> <li>▪ Added "NOTE: Comparison 3D-CRT dose volume histogram (DVH) in color"</li> </ul>
10-01-2021	<p>In Coding section (Effective 10-01-2021) Added ICD-10 codes: C56.3, C79.3</p>
04-20-2022	<p>Added Policy Guideline Section</p> <ul style="list-style-type: none"> <li>▪ Moved the following statement from the policy section to the policy guideline section: <ul style="list-style-type: none"> <li>A. The American Society for Therapeutic Radiology and Oncology (ASTRO) 2019 has a model policy which describes the indications for IMRT: "IMRT is considered reasonable and necessary in instances where sparing the surrounding normal tissue is of added benefit to the patient. Examples of reasons why IMRT might be advantageous include the following: <ol style="list-style-type: none"> <li>1. The target volume is in close proximity to one or more critical structures and a steep dose gradient outside the target must be achieved and avoid exceeding the tolerance dose to the critical structure(s).</li> <li>2. A decrease in the amount of dose inhomogeneity in a large treatment volume is required to avoid an excessive dose "hotspot" within the treated volume to avoid excessive early or late normal tissue toxicity.</li> <li>3. A non-IMRT technique would substantially increase the probability of clinically meaningful normal tissue toxicity.</li> <li>4. The same or an immediately adjacent area has been previously irradiated, and the dose distribution within the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue."</li> </ol> </li> </ul> </li> </ul> <p>Updated Coding Section</p> <ul style="list-style-type: none"> <li>▪ Removed Coding Bullets <ul style="list-style-type: none"> <li>• The following CPT codes are used for simple and complex IMRT delivery: 77385, 77386.</li> <li>• The following codes may be used for IMRT: G6015, G6016.</li> <li>• Code 77301 remains valid.</li> <li>• The following CPT code may also be used: 77338.</li> </ul> </li> <li>▪ Removed CPT codes 77300, 77301, 77332, 77333, 77334</li> <li>▪ Converted ICD-10 Codes to ranges</li> </ul>
10-13-2022	<p>Updated Policy Section Section A9a:</p>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<ul style="list-style-type: none"> <li>▪ Added: "Left breast cancer"</li> <li>▪ Removed: "Heart-3D results in <math>\geq 25</math> % of heart receiving <math>\geq 30</math>Gy;"</li> </ul> <p>Section A9b</p> <ul style="list-style-type: none"> <li>▪ Added: "Right breast cancer with" <ul style="list-style-type: none"> <li>i. Lung—3D results in <math>\geq 30</math>% of ipsilateral lung receiving <math>\geq 20</math> Gy, OR 3D results in <math>\geq 20</math>% of combined lung volume receiving <math>\geq 20</math>Gy;</li> <li>OR</li> <li>ii. Skin / Soft Tissue—3D results in <math>\geq 5</math>% of intended breast receiving <math>\geq 7</math>% of prescribed dose OR Medial lesion where 3D results in <math>\geq 10</math>% of contralateral breast receiving <math>\geq 10</math>Gy.</li> </ul> </li> </ul> <p>Section A11:</p> <ul style="list-style-type: none"> <li>▪ Added: "Stage III cancer"</li> <li>▪ Removed: "when at least one of the following is met: Heart—3D results in <math>\geq 50</math>% of heart receiving <math>\geq 30</math> Gy; <b>OR</b> Lung—3D result in <math>\geq 30</math>% of non-cancerous combined lung volume receiving <math>\geq 20</math> Gy"</li> </ul> <p>Updated Coding Section:</p> <ul style="list-style-type: none"> <li>▪ Removed ICD-10 codes: D40.0, D32.0-D32.9, D33.0-D33.9, D35.1-D35.9, C79.89</li> <li>▪ Changed ICD-10 code range C69.01-C69.9 to C69.01-C69.92, C43.0-C44.9 to C43.0-C43.4 and C44.00-C44.49, C75.0-C75.9 to C75.0-C75.5</li> <li>▪ Converted ICD-10 codes to ranges to include all ICD-10 codes within range: D03.0-D03.4</li> <li>▪ Added ICD-10 Range to include all ICD-10 codes within range: D0.40-D04.4 and C21.0-C21.8</li> <li>▪ Added ICD-10 code: C55, C50.012, C50.022, C50.112, C50.122, C50.212, C50.222, C50.312, C50.322, C50.412, C50.422, C50.512, C50.522, C50.612, C50.622, C50.812, C50.822, C50.912, C50.922, D05.02, D05.82, D05.92, D48.62</li> </ul>
09-12- 2023	<p>Updated Coding Section</p> <ul style="list-style-type: none"> <li>▪ Removed ICD-10 Codes</li> </ul>
10-08-2024	Medical policy reviewed with no edit changes.
09-23-2025	<p>Updated Description Section</p> <p>Updated Policy Section</p> <p>Section C.2.</p> <ul style="list-style-type: none"> <li>▪ Removed: The prescription which defines the goals and requirements of the treatment plan, including the specific dose constraints to the target and nearby critical structures.</li> <li>▪ Added: The plan which defines the goals and requirements of the treatment plan, including the specific dose objectives to the target and nearby critical structures.</li> </ul> <p>Section C.4.</p> <ul style="list-style-type: none"> <li>▪ Removed: Signed IMRT inverse plan that meets prescribed dose constraints for the planning target volume (PTV) and surrounding normal tissue.</li> <li>▪ Added: Signed IMRT plan that corresponds with the approved prescription.</li> </ul> <p>Section C.5</p> <ul style="list-style-type: none"> <li>▪ Removed: The target verification methodology must include the following: <ul style="list-style-type: none"> <li>a. Documentation of the clinical treatment volume (CTV) and the planning target volume (PTV).</li> <li>b. Documentation of immobilization and patient positioning.</li> </ul> </li> </ul>

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

<b>REVISIONS</b>	
	<p>Section C.6.</p> <ul style="list-style-type: none"> <li>▪ Added: The medical record must include the following:               <ol style="list-style-type: none"> <li>a. Documentation of clinically appropriate GTV/CTV/ITV/PTV.</li> <li>b. Documentation of dose volume histograms for targets and OAR's.</li> <li>c. Documentation of immobilization and patient positioning.</li> </ol> </li> </ul>
	<p>Updated Policy Guidelines Section Section A.</p> <ul style="list-style-type: none"> <li>▪ Removed: 2019</li> <li>▪ Added: 2024</li> <li>▪ Removed:               <ol style="list-style-type: none"> <li>1. The target volume is in close proximity to one or more critical structures and a steep dose gradient outside the target must be achieved and avoid exceeding the tolerance dose to the critical structure(s).</li> <li>2. A decrease in the amount of dose inhomogeneity in a large treatment volume is required to avoid an excessive dose "hotspot" within the treated volume to avoid excessive early or late normal tissue toxicity.</li> <li>3. A non-IMRT technique would substantially increase the probability of clinically meaningful normal tissue toxicity.</li> <li>4. The same or an immediately adjacent area has been previously irradiated, and the dose distribution within the patient must be sculpted to avoid exceeding the cumulative tolerance dose of nearby normal tissue."</li> </ol> </li> <li>▪ Added: IMRT is considered reasonable and medically necessary in instances where sparing the surrounding normal tissue is of added benefit to the patient. Examples of reasons why IMRT might be advantageous include the following:               <ol style="list-style-type: none"> <li>1. Instances in which clinically relevant tolerances of normal tissues are exceeded for a single plan or in the re-irradiation setting.</li> <li>2. IMRT is indicated if the patient's general medical condition (namely, the performance status) justifies aggressive local therapy to one or more deposits of metastatic cancer in an effort to achieve total disease clearance in the setting of oligometastatic disease.</li> </ol> </li> </ul>
	<p>Updated Reference Section</p> <ul style="list-style-type: none"> <li>▪ Added: American Society for Therapeutic Radiology and Oncology (ASTRO) Model Policy on Intensity Modulated Radiation Therapy (IMRT) 06-30-2024.</li> </ul>
01-01-2026	<p>Updated Coding Section</p> <ul style="list-style-type: none"> <li>▪ Removed Deleted Codes 77385, 77386, G6015 and G6016 (eff. 01-01-2026)</li> <li>▪ Added 77402, 77407 and 77412 (eff. 01-01-2026)</li> </ul>
05-26-2026	<b>Retired</b>

## REFERENCES

1. American Society for Therapeutic Radiology and Oncology (ASTRO) Model Policy on Intensity Modulated Radiation Therapy (IMRT) 06-30-2024.
2. Sung K, Lee KC, Lee SH, et al. Cardiac dose reduction with breathing adapted radiotherapy using self respiration monitoring system for left-sided breast cancer. *Radiat Oncol J.* Jun 2014;32(2):84-94. PMID 25061577

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

3. Kaza E, Dunlop A, Panek R, et al. Lung volume reproducibility under ABC control and self-sustained breath-holding. *J Appl Clin Med Phys*. Mar 2017;18(2):154-162. PMID 28300372
4. Coon AB, Dickler A, Kirk MC, et al. Tomotherapy and multifield intensity-modulated radiotherapy planning reduce cardiac doses in left-sided breast cancer patients with unfavorable cardiac anatomy. *Int J Radiat Oncol Biol Phys*. Sep 1 2010;78(1):104-110. PMID 20004529
5. Dayes I, Rumble RB, Bowen J, et al. Intensity-modulated radiotherapy in the treatment of breast cancer. *Clin Oncol*. Sep 2012;24(7):488-498. PMID 22748561
6. Pignol JP, Olivetto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. *J Clin Oncol*. May 1 2008;26(13):2085-2092. PMID 18285602
7. Pignol JP, Truong P, Rakovitch E, et al. Ten years results of the Canadian breast intensity modulated radiation therapy (IMRT) randomized controlled trial. *Radiother Oncol*. Dec 2016;121(3):414-419. PMID 27637858
8. Donovan EM, Bleackley NJ, Evans PM, et al. Dose-position and dose-volume histogram analysis of standard wedged and intensity modulated treatments in breast radiotherapy. *Br J Radiol*. Dec 2002;75(900):967-973. PMID 12515705
9. Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. *Radiother Oncol*. Mar 2007;82(3):254-264. PMID 17224195
10. Barnett GC, Wilkinson J, Moody AM, et al. A randomised controlled trial of forward-planned radiotherapy (IMRT) for early breast cancer: baseline characteristics and dosimetry results. *Radiother Oncol*. Jul 2009;92(1):34-41. PMID 19375808
11. Barnett GC, Wilkinson JS, Moody AM, et al. Randomized controlled trial of forward-planned intensity modulated radiotherapy for early breast cancer: interim results at 2 years. *Int J Radiat Oncol Biol Phys*. Feb 1 2012;82(2):715-723. PMID 21345620
12. Hardee ME, Raza S, Becker SJ, et al. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. *Int J Radiat Oncol Biol Phys*. Mar 1 2012;82(3):e415-423. PMID 22019349
13. Guttman DM, Gabriel P, Kennedy C, et al. Comparison of acute toxicities between contemporary forward-planned 3D conformal radiotherapy and inverse-planned intensity-modulated radiotherapy for whole breast radiation. *Breast J*. Mar 2018;24(2):128-132. PMID 28703444
14. Rudat V, Alaradi AA, Mohamed A, et al. Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison. *Radiat Oncol*. Mar 21 2011;6:26. PMID 21418616
15. Rastogi K, Sharma S, Gupta S, et al. Dosimetric comparison of IMRT versus 3DCRT for post-mastectomy chest wall irradiation. *Radiat Oncol J*. Mar 2018;36(1):71-78. PMID 29621872
16. Bezjak A, Rumble RB, Rodrigues G, et al. Intensity-modulated radiotherapy in the treatment of lung cancer. *Clin Oncol*. Sep 2012;24(7):508-520. PMID 22726417
17. Liao ZX, Komaki RR, Thames HD, Jr., et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. *Int J Radiat Oncol Biol Phys*. Mar 1 2010;76(3):775-781. PMID 19515503

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

18. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. *J Clin Oncol*. Jan 2017;35(1):56-62. PMID 28034064
19. Harris JP, Murphy JD, Hanlon AL, et al. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. *Int J Radiat Oncol Biol Phys*. Mar 15 2014;88(4):872-884. PMID 24495591
20. Shirvani SM, Juloori A, Allen PK, et al. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. *Int J Radiat Oncol Biol Phys*. Sep 1 2013;87(1):139-147. PMID 23920393
21. Ling DC, Hess CB, Chen AM, et al. Comparison of toxicity between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer. *Clin Lung Cancer*. Jan 2016;17(1):18-23. PMID 26303127
22. Koshy M, Malik R, Spiotto M, et al. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy. *Lung Cancer*. Jun 2017;108:222-227. PMID 28625640
23. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed June 13, 2018.
24. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. Version 4.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf). Accessed June 13, 2018.
25. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/sclc.pdf](https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf). Accessed June 13, 2018.
26. Smith BD, Bellon JR, Blitzblau R, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. *Pract Radiat Oncol*. May - Jun 2018;8(3):145-152. PMID 29545124
27. Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. *Pract Radiat Oncol*. Jul - Aug 2018;8(4):245-250. PMID 29625898
28. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stages I to IIIA resectable non-small-cell lung cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary. *J Oncol Pract*. Jul 2017;13(7):449-451. PMID 28441082
29. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). *Lancet*. Aug 13-19 2005;366(9485):572-578. PMID 16099293
30. Thompson IM, Jr., Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *JAMA*. Nov 15 2006;296(19):2329-2335. PMID 17105795
31. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol*. Jun 20 2009;27(18):2924-2930. PMID 19433689

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

32. Thompson IM, Valicenti RK, Albertsen P, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. *J Urol*. Aug 2013;190(2):441-449. PMID 23707439
33. Yu T, Zhang Q, Zheng T, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. *PLoS One*. May 2016;11(5):e0154499. PMID 27171271
34. Bauman G, Rumble RB, Chen J, et al. Intensity-modulated radiotherapy in the treatment of prostate cancer. *Clin Oncol (R Coll Radiol)*. Sep 2012;24(7):461-473. PMID 22673744
35. Hummel S, Simpson EL, Hemingway P, et al. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. *Health Technol Assess*. Oct 2010;14(47):1-108, iii-iv. PMID 21029717
36. Viani GA, Viana BS, Martin JE, et al. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial. *Cancer*. Jul 01 2016;122(13):2004-2011. PMID 27028170
37. Sujenthiran A, Nossiter J, Charman SC, et al. National population-based study comparing treatment-related toxicity in men who received intensity modulated versus 3-dimensional conformal radical radiation therapy for prostate cancer. *Int J Radiat Oncol Biol Phys*. Dec 1 2017;99(5):1253-1260. PMID 28974414
38. Michalski JM, Yan Y, Watkins-Bruner D, et al. Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial. *Int J Radiat Oncol Biol Phys*. Dec 1 2013;87(5):932-938. PMID 24113055
39. Vora SA, Wong WW, Schild SE, et al. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. *J Urol*. Aug 2013;190(2):521-526. PMID 23415964
40. Wong WW, Vora SA, Schild SE, et al. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy. *Cancer*. Dec 1 2009;115(23):5596-5606. PMID 19670452
41. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. *Int J Radiat Oncol Biol Phys*. Jan 1 2008;70(1):67-74. PMID 17765406
42. Xu N, Rossi PJ, Jani AB. Toxicity analysis of dose escalation from 75.6 Gy to 81.0 Gy in prostate cancer. *Am J Clin Oncol*. Feb 2011;34(1):11-15. PMID 20101167
43. Eade TN, Hanlon AL, Horwitz EM, et al. What dose of external-beam radiation is high enough for prostate cancer? *Int J Radiat Oncol Biol Phys*. Jul 1 2007;68(3):682-689. PMID 17398026
44. Alongi F, Fiorino C, Cozzarini C, et al. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. *Radiother Oncol*. Nov 2009;93(2):207-212. PMID 19766338
45. Massacesi M, Cilla S, Deodato F, et al. Hypofractionated intensity-modulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. *Anticancer Res*. Jun 2013;33(6):2785-2789. PMID 23749942
46. Katayama S, Hahl G, Kessel K, et al. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with integrated boost to the prostate bed - initial results of the PLATIN 3 Trial. *BMC Cancer*. Jan 14 2014;14:20. PMID 24422782

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

47. Katayama S, Striecker T, Kessel K, et al. Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. *Int J Radiat Oncol Biol Phys*. Nov 15 2014;90(4):926-933. PMID 25216858
48. Corbin KS, Kunnavakkam R, Eggener SE, et al. Intensity modulated radiation therapy after radical prostatectomy: Early results show no decline in urinary continence, gastrointestinal, or sexual quality of life. *Pract Radiat Oncol*. Apr-Jun 2013;3(2):138-144. PMID 24674317
49. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate cancer. Version 3.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed July 2, 2018.
50. Freedland SJ, Rumble RB, Finelli A, et al. Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. *J Clin Oncol*. Dec 1 2014;32(34):3892-3898. PMID 25366677
51. Nguyen PL, Aizer A, Assimos DG, et al. ACR Appropriateness Criteria(R) definitive external-beam irradiation in stage T1 and T2 prostate cancer. *Am J Clin Oncol*. Jun 2014;37(3):278-288. PMID 25180754
52. Ursino S, D'Angelo E, Mazzola R, et al. A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy : A systematic review by the Italian Head and Neck Radiotherapy Study Group. *Strahlenther Onkol*. Nov 2017;193(11):877-889. PMID 28616822
53. Marta GN, Silva V, de Andrade Carvalho H, et al. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. *Radiother Oncol*. Jan 2014;110(1):9-15. PMID 24332675
54. Samson DM, Ratko TA, Rothenberg BM, et al. *Comparative effectiveness and safety of radiotherapy treatments for head and neck cancer (Comparative Effectiveness Review No. 20)*. Rockville, MD: Agency for Healthcare Research and Quality; 2010.
55. Ratko TA, Douglas G, de Souza JA, et al. *Radiotherapy Treatments for Head and Neck Cancer Update (Comparative Effectiveness Review No. 144)*. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
56. Gupta T, Agarwal J, Jain S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. *Radiother Oncol*. Sep 2012;104(3):343-348. PMID 22853852
57. Ghosh-Laskar S, Yathiraj PH, Dutta D, et al. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. *Head Neck*. Apr 2016;38(Suppl 1):E1481-1487. PMID 26561342
58. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. *Int J Radiat Oncol Biol Phys*. Nov 15 2006;66(4):981-991. PMID 17145528
59. Nutting CM, Morden JP, Harrington KJ, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol*. Feb 2011;12(2):127-136. PMID 21236730
60. Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

- for the treatment of nasopharyngeal carcinoma. *Radiother Oncol*. Sep 2012;104(3):286-293. PMID 22995588
61. Qiu WZ, Peng XS, Xia HQ, et al. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma. *J Cancer Res Clin Oncol*. Aug 2017;143(8):1563-1572. PMID 28342002
  62. Huang TL, Chien CY, Tsai WL, et al. Long-term late toxicities and quality of life for survivors of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy versus non-intensity-modulated radiotherapy. *Head Neck*. Apr 2016;38(Suppl 1):E1026-1032. PMID 26041548
  63. Vergeer MR, Doornaert PA, Rietveld DH, et al. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. *Int J Radiat Oncol Biol Phys*. May 1 2009;74(1):1-8. PMID 19111400
  64. Rusthoven KE, Raben D, Ballonoff A, et al. Effect of radiation techniques in treatment of oropharynx cancer. *Laryngoscope*. Apr 2008;118(4):635-639. PMID 18176348
  65. Bhatia A, Rao A, Ang KK, et al. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. *Head Neck*. Jul 2010;32(7):829-836. PMID 19885924
  66. Schwartz DL, Lobo MJ, Ang KK, et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. *Int J Radiat Oncol Biol Phys*. Jul 15 2009;74(4):1083-1091. PMID 19095376
  67. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Head and Neck Cancers. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/head-and-neck.pdf](https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf). Accessed June 26, 2018.
  68. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Thyroid Carcinoma. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/thyroid.pdf](https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf). Accessed June 26, 2018.
  69. Boda-Heggemann J, Hofheinz RD, Weiss C, et al. Combined adjuvant radiochemotherapy with IMRT/XELOX improves outcome with low renal toxicity in gastric cancer. *Int J Radiat Oncol Biol Phys*. Nov 15 2009;75(4):1187-1195. PMID 19409725
  70. Boda-Heggemann J, Weiss C, Schneider V, et al. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. *Strahlenther Onkol*. May 2013;189(5):417-423. PMID 23558673
  71. Fuller CD, Dang ND, Wang SJ, et al. Image-guided intensity-modulated radiotherapy (IG-IMRT) for biliary adenocarcinomas: Initial clinical results. *Radiother Oncol*. Aug 2009;92(2):249-254. PMID 19324442
  72. Lee KJ, Yoon HI, Chung MJ, et al. A comparison of gastrointestinal toxicities between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for pancreatic cancer. *Gut Liver*. Mar 23 2016;10(2):303-309. PMID 26470767
  73. Prasad S, Cambridge L, Huguet F, et al. Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. *Pract Radiat Oncol*. Mar-Apr 2016;6(2):78-85. PMID 26577010
  74. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer Radiother*. Jul 2016;20(5):370-376. PMID 27368915

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

75. Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. *Int J Radiat Oncol Biol Phys*. Nov 1 2013;87(3):542-548. PMID 24074927
76. Shih KK, Hajj C, Kollmeier M, et al. Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy. *Gynecol Oncol*. Oct 2016;143(1):18-21. PMID 27486131
77. Chen CC, Wang L, Lu CH, et al. Comparison of clinical outcomes and toxicity in endometrial cancer patients treated with adjuvant intensity-modulated radiation therapy or conventional radiotherapy. *J Formos Med Assoc*. Dec 2014;113(12):949-955. PMID 24144528
78. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. *Int J Radiat Oncol Biol Phys*. Apr 1 2007;67(5):1438-1444. PMID 17394944
79. Rattan R, Kapoor R, Bahl A, et al. Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: a prospective study. *Ann Transl Med*. Feb 2016;4(4):70. PMID 27004217
80. Sun Z, Adam MA, Kim J, et al. Intensity-modulated radiation therapy is not associated with perioperative or survival benefit over 3D-conformal radiotherapy for rectal cancer. *J Gastrointest Surg*. Jan 2017;21(1):106-111. PMID 27510332
81. Huang CM, Huang MY, Tsai HL, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. *J Radiat Res*. Mar 01 2017;58(2):247-259. PMID 27738080
82. Chuong MD, Freilich JM, Hoffe SE, et al. Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal. *Gastrointest Cancer Res*. Mar 2013;6(2):39-45. PMID 23745158
83. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs. conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. *Radiother Oncol*. May 2013;107(2):189-194. PMID 23692961
84. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? *Radiat Oncol*. Nov 2012;7:201. PMID 23190693
85. Devisetty K, Mell LK, Salama JK, et al. A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy. *Radiother Oncol*. Nov 2009;93(2):298-301. PMID 19717198
86. Pepek JM, Willett CG, Wu QJ, et al. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. *Int J Radiat Oncol Biol Phys*. Dec 1 2010;78(5):1413-1419. PMID 20231064
87. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Gastric Cancer. Version 2.2018. [https://www.nccn.org/professionals/physician\\_gls/pdf/gastric.pdf](https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf). Accessed May 31, 2018.
88. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Hepatobiliary Cancers. Version 1.2018.

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

- [https://www.nccn.org/professionals/physician\\_gls/PDF/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf). Accessed May 31, 2018.
89. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Pancreatic Adenocarcinoma. Version 1.2018.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/pancreatic.pdf](https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf). Accessed May 31, 2018.
  90. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Cervical Cancer. Version 1.2018.  
[https://www.nccn.org/professionals/physician\\_gls/PDF/cervical.pdf](https://www.nccn.org/professionals/physician_gls/PDF/cervical.pdf). Accessed May 31, 2018.
  91. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Uterine Neoplasms. Version 2.2018.  
[https://www.nccn.org/professionals/physician\\_gls/PDF/uterine.pdf](https://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf). Accessed May 31, 2018.
  92. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Ovarian Cancer. Version 2.2018.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/ovarian.pdf](https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf). Accessed May 31, 2018.
  93. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Anal Carcinoma. Version 1.2018.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/anal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/anal.pdf). Accessed May 31, 2018.
  94. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Rectal Cancer. Version 1.2018.  
[https://www.nccn.org/professionals/physician\\_gls/pdf/rectal.pdf](https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf). Accessed May 31, 2018.
  95. Expert Panel on Radiation Oncology-Rectal/Anal Cancer, Hong TS, Pretz JL, et al. ACR Appropriateness Criteria(R)-Anal Cancer. *Gastrointest Cancer Res*. Jan 2014;7(1):4-14. PMID 24558509
  96. Amelio D, Lorentini S, Schwarz M, et al. Intensity-modulated radiation therapy in newly diagnosed glioblastoma: a systematic review on clinical and technical issues. *Radiother Oncol*. Dec 2010;97(3):361-369. PMID 20926149
  97. Gupta T, Wadasadawala T, Master Z, et al. Encouraging early clinical outcomes with helical tomotherapy-based image-guided intensity-modulated radiation therapy for residual, recurrent, and/or progressive benign/low-grade intracranial tumors: a comprehensive evaluation. *Int J Radiat Oncol Biol Phys*. Feb 1 2012;82(2):756-764. PMID 21345610
  98. Edwards AA, Keggin E, Plowman PN. The developing role for intensity-modulated radiation therapy (IMRT) in the non-surgical treatment of brain metastases. *Br J Radiol*. Feb 2010;83(986):133-136. PMID 20019176
  99. Fuller CD, Choi M, Forthuber B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. *Radiat Oncol*. Jul 14 2007;2:26. PMID 17629934
  100. MacDonald SM, Ahmad S, Kachris S, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. *J Appl Clin Med Phys*. Apr 19 2007;8(2):47-60. PMID 17592465
  101. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. *Int J Radiat Oncol Biol Phys*. Mar 1 2006;64(3):892-897. PMID 16458777
  102. Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. *Am J Clin Oncol*. Apr 2014;37(2):177-181. PMID 23211224

**This medical policy has been retired and is not currently active as of January 1, 2026. No further reviews or updates will be made to this medical policy. For questions regarding coverage of this service, please contact Blue Cross and Blue Shield of Kansas Customer Service or your Provider Network Solutions representative**

103. Milker-Zabel S, Zabel-du Bois A, Huber P, et al. Intensity-modulated radiotherapy for complex-shaped meningioma of the skull base: long-term experience of a single institution. *Int J Radiat Oncol Biol Phys*. Jul 1 2007;68(3):858-863. PMID 17379447
104. Mackley HB, Reddy CA, Lee SY, et al. Intensity-modulated radiotherapy for pituitary adenomas: the preliminary report of the Cleveland Clinic experience. *Int J Radiat Oncol Biol Phys*. Jan 01 2007;67(1):232-239. PMID 17084541
105. Sajja R, Barnett GH, Lee SY, et al. Intensity-modulated radiation therapy (IMRT) for newly diagnosed and recurrent intracranial meningiomas: preliminary results. *Technol Cancer Res Treat*. Dec 2005;4(6):675-682. PMID 16292888
106. Gondi V, Pugh SL, Tome WA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. *J Clin Oncol*. Dec 1 2014;32(34):3810-3816. PMID 25349290
107. Zhou L, Liu J, Xue J, et al. Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer. *Radiat Oncol*. May 21 2014;9:117. PMID 24884773
108. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2018. [https://www.nccn.org/professionals/physician\\_gls/PDF/cns.pdf](https://www.nccn.org/professionals/physician_gls/PDF/cns.pdf). Accessed June 13 2018.

#### **OTHER REFERENCES**

1. Blue Cross and Blue Shield of Kansas Radiology Liaison Committee; February 2008, February 2009; February 2010; May 2019.
2. Blue Cross and Blue Shield of Kansas Radiology Liaison Committee, Consent Ballot, January 2009; July 2019.
3. Blue Cross and Blue Shield of Kansas Oncology Liaison Committee; June 2022, July 2023.
4. Blue Cross and Blue Shield of Kansas Oncology Liaison Committee, Consent Ballot, July 2022.
5. Blue Cross and Blue Shield of Kansas Medical Consultant, Practicing Board-Certified Radiation Oncologist (548), September 2011.
6. Blue Cross and Blue Shield of Kansas Medical Consultant, Practicing Board Certified Radiation Oncologist (548), March 2012.
7. Blue Cross and Blue Shield of Kansas Medical Consultant, Practicing Board Certified Radiation Oncologist (548), April 2012.